Makers Laboratories has scheduled its 41st Annual General Meeting (AGM) for Friday, August 7, 2026, at 12.30 p.m. The meeting will be conducted through Video Conferencing or Other Audio Visual Means (VC/OAVM). The company has communicated this to BSE Ltd., detailing the procedural aspects for shareholder participation and voting.

The facility for remote e-voting will be available to members from Monday, August 3, 2026, at 9.00 a.m. until Thursday, August 6, 2026, at 5.00 p.m. Shareholders holding shares in physical or dematerialized form as of the cut-off date, Friday, July 31, 2026, are eligible to participate. E-voting services are provided by National Securities Depository Limited (NSDL), and members who have already cast their votes remotely may attend the meeting but cannot vote again.

The Notice of the 41st AGM and the Annual Report for the financial year 2025-26 have been dispatched electronically to shareholders. Physical copies have been dispensed with in accordance with relevant MCA and SEBI circulars. Documents are available for download on the company's website and the NSDL e-voting portal.

Key Meeting Dates

Shareholders requiring login credentials for e-voting or those needing assistance with grievances may contact Piyush Ajmera, Company Secretary, at investors@makerslabs.com . The voting rights of members are proportionate to their shareholding in the paid-up equity share capital of the company.

Makers Laboratories Limited reported a standalone net loss of ₹1.72 crore for the financial year ended March 31, 2026, reversing its net profit of ₹4.64 crore in the previous year. The company’s total income declined to ₹50.94 crore in FY26 from ₹53.87 crore in the preceding financial year.

The standalone operations resulted in a profit before interest, depreciation, and taxation of ₹1.32 crore, significantly lower than the ₹8.71 crore recorded in FY25. After accounting for depreciation, finance costs, and tax expenses, the company posted a net loss for the period. The financial figures for the current year are not strictly comparable to the previous year, as the prior year’s operations included other income and a profit of ₹18.50 crore from the sale of office premises in Mumbai.

The company attributed the decline in financial performance to lower growth in its generic formulations business due to reduced prevalence of acute diseases and decreased demand for liquid injectables. Additionally, depreciation charges, finance costs, and other overheads related to its new ophthalmic eye drops manufacturing facility in GIDC, Naroda, Ahmedabad, which was commercialised in FY21, impacted profitability. This unit has started manufacturing eye drops for the Eurasia market, with more product dossiers under registration in Rest of World (ROW) markets.

On a consolidated basis, sales and other income rose to ₹142.30 crore in FY26 from ₹132.64 crore in FY25, representing a growth of 7%. However, consolidated net profit after non-controlling interest fell to ₹2.35 crore from ₹7.49 crore in the previous year. The company’s subsidiary, Resonance Specialties Ltd., in which it holds a 45.48% stake, reported a total income of ₹91.99 crore and a net profit of ₹10.40 crore for the year.

Financial Highlights

The Board of Directors has recommended that no dividend be declared for the financial year ended March 31, 2026, in view of the losses incurred in the standalone financials. The company’s research and development expenditure for the year stood at ₹21.27 lacs, constituting 0.42% of the turnover.